XtalPi and Signet Expand AI Drug Discovery Collaboration to Novel Cancer Target
Excerpt from the Press Release:
SHENZHEN, China and BOSTON, Oct. 27, 2021 /PRNewswire/ — Signet Therapeutics and XtalPi Inc., a physics-based, AI-powered drug R&D company, announced the expansion of their AI drug discovery collaboration to include a new first-in-class program against a novel cancer target identified by Signet. The two companies entered into a strategic collaboration in 2020 and successfully identified pre-clinical candidates for a new gastric cancer target in approximately six months. The follow-on project will continue to combine XtalPi’s AI drug discovery platform with Signet’s unique novel organoid disease models to generate pipeline candidates for Signet and advance them toward clinical trials.
A significant challenge to developing new therapeutics is the ability to expand the search beyond known structures and accurately screen through a copious supply of novel molecules to identify top candidates with a desirable drug property profile indicative of development potential. Pharmacodynamics is a key factor in lead optimization and drug design. However, traditional cell-based in vitro studies have considerable limitations in modeling drug effects in the human body and often produce unreliable efficacy data that can lead to clinical failure.
Click the button below to read the entire Press Release:
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?